Parkinsonism & Related Disorders
Volume 16, Issue 5 , Pages 316-323 , June 2010

Long-term efficacy and safety of botulinum toxin type A (Dysport) in cervical dystonia

  • Daniel Truong

      Affiliations

    • The Parkinson’s and Movement Disorder Institute, 9940 Talbert Avenue, #204, Fountain Valley, CA 92708, USA
    • Corresponding Author InformationCorresponding author. Tel.: +1 714 378 5062; fax: +1 714 378 5061.
    • ,
  • Matthew Brodsky

      Affiliations

    • Oregon Health & Science University, Portland, OR, USA
    • ,
  • Mark Lew

      Affiliations

    • Keck/University of Southern California School of Medicine, University of Southern California, Los Angeles, CA, USA
    • ,
  • Allison Brashear

      Affiliations

    • Wake Forest University Health Sciences, Department of Neurology, Winston-Salem, NC, USA
    • ,
  • Joseph Jankovic

      Affiliations

    • Department of Neurology, Parkinson’s Disease Center and Movement Disorders Clinic, Baylor College of Medicine, Houston, TX, USA
    • ,
  • Eric Molho

      Affiliations

    • Parkinson’s Disease and Movement Disorders Center, Albany Medical Center, Albany, USA
    • ,
  • Olga Orlova

      Affiliations

    • Moscow Medical Academy and Academy Clinic of Neurology and Stomatology Cecil-plus, Moscow, Russia
    • ,
  • Sofia Timerbaeva

      Affiliations

    • Research Center of Neurology, Russian Academy of Medical Sciences, Moscow, Russia
    • ,
  •  On behalf of the Global Dysport Cervical Dystonia Study Group

      Affiliations

    • Members of the Global Dysport Cervical Dystonia Study Group were: Dr. S. Aurora (Seattle, USA), Dr. A. Brashear (Winston-Salem, USA), Dr. M. Brodsky (Portland, USA), Dr. A. Ahmed (Phoenix, USA), Dr. C. Comella (Chicago, USA), Dr. D. Dykstra (Minneapolis, USA), Dr. M. Evatt (Atlanta, USA), Dr. H. Fernandez (Gainesville, USA), Dr. J. Jankovic (Houston, USA), Dr. P. Jozefczyk (Pittsburgh, USA), Dr. M. Lew (Los Angeles, USA), Dr. E. Molho (Albany, USA), Professor O. Orlova (Moscow, Russian Federation), Dr. P. O’Suilleabhain (Dallas, USA), Dr. S. Perfiliev (St. Petersburg, Russian Federation), Dr. R. Rodnitzky (Iowa City, USA), Dr. C. Singer (Miami, USA), Professor A. Skoromets (St. Petersburg, Russian Federation), Dr. S. Timerbaeva (Moscow, Russian Federation) and Dr. D. Truong (Fountain Valley, USA).

Received 11 November 2009 ,Revised 4 February 2010 ,Accepted 7 March 2010.

References 

  1. Van Zandijcke M. Cervical dystonia (spasmodic torticollis). Some aspects of the natural history. Acta Neurol Belg. 1995;95:210–215
  2. Jankovic J, Leder S, Warner D, Schwartz K. Cervical dystonia: clinical findings and associated movement disorders. Neurology. 1991;41:1088–1091
  3. Kutvonen O, Dastidar P, Nurmikko T. Pain in spasmodic torticollis. Pain. 1997;69:279–286
  4. Jankovic J, Tsui J, Bergeron C. Prevalence of cervical dystonia and spasmodic torticollis in the United States general population. Parkinsonism Relat Disord. 2007;13:411–416
  5. Rondot P, Marchand MP, Dellatolas G. Spasmodic torticollis–review of 220 patients. Can J Neurol Sci. 1991;18:143–151
  6. Molho ES, Agarwal N, Regan K, Higgins DS, Factor SA. Effect of cervical dystonia on employment: a retrospective analysis of the ability of treatment to restore premorbid employment status. Mov Disord. 2009;24:1384–1387
  7. Simpson DM, Blitzer A, Brashear A, Comella C, Dubinsky R, Hallett M, et al. Assessment: botulinum neurotoxin for the treatment of movement disorders (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 2008;70:1699–1706
  8. Odergren T, Tollback A, Borg J. Electromyographic single motor unit potentials after repeated botulinum toxin treatments in cervical dystonia. Electroencephalogr Clin Neurophysiol. 1994;93:325–329
  9. Costa J, Espirito-Santo C, Borges A, Ferreira JJ, Coelho M, Moore P, et al. Botulinum toxin type A therapy for cervical dystonia. Cochrane Database Syst Rev. 2005;CD003633
  10. Jankovic J, Brin MF. Therapeutic uses of botulinum toxin. N Engl J Med. 1991;324:1186–1194
  11. Consky ES, Lang AE. Clinical assessments of patients with cervical dystonia. In:  Jankovic J,  Hallett M editor. Therapy with botulinum toxin. New York: M. Dekker; 1994;p. 211–237
  12. Poewe W, Deuschl G, Nebe A, Feifel E, Wissel J, Benecke R, et al. What is the optimal dose of botulinum toxin A in the treatment of cervical dystonia? Results of a double blind, placebo controlled, dose ranging study using Dysport. German Dystonia Study Group. J Neurol Neurosurg Psychiatry. 1998;64:13–17
  13. Wissel J, Kanovsky P, Ruzicka E, Bares M, Hortova H, Streitova H, et al. Efficacy and safety of a standardised 500 unit dose of Dysport (Clostridium botulinum toxin type A haemaglutinin complex) in a heterogeneous cervical dystonia population: results of a prospective, multicentre, randomised, double-blind, placebo-controlled, parallel group study. J Neurol. 2001;248:1073–1078
  14. Truong D, Duane DD, Jankovic J, Singer C, Seeberger LC, Comella CL, et al. Efficacy and safety of botulinum type A toxin (Dysport) in cervical dystonia: results of the first US randomized, double-blind, placebo-controlled study. Mov Disord. 2005;20:783–791
  15. Ware JE. How to Score Version 2 of the SF-36 Health Survey. 2002.
  16. Haussermann P, Marczoch S, Klinger C, Landgrebe M, Conrad B, Ceballos-Baumann A. Long-term follow-up of cervical dystonia patients treated with botulinum toxin A.. Mov Disord. 2004;19:303–308
  17. Kessler KR, Skutta M, Benecke R. Long-term treatment of cervical dystonia with botulinum toxin A: efficacy, safety, and antibody frequency. German Dystonia Study Group. J Neurol. 1999;246:265–274

☆ The review of this paper was entirely handled by the Co-Editor-in-Chief, Ronald Pfeiffer.

☆☆ Clinical trials information: (NCT00257660 and NCT00288509; clinicaltrials.gov).

PII: S1353-8020(10)00055-6

doi: 10.1016/j.parkreldis.2010.03.002

Parkinsonism & Related Disorders
Volume 16, Issue 5 , Pages 316-323 , June 2010

Article Tools

* Image Usage & Resolution